Esperion Therapeutics ESPR Proceeds From Warrant Exercises
Proceeds From Warrant Exercises at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's proceeds from warrant exercises.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's proceeds from warrant exercises?
- Esperion Therapeutics (ESPR) reported proceeds from warrant exercises of $16.22M in Q1 2026.
- What does proceeds from warrant exercises mean?
- This metric represents the cash inflows received by the company when holders of warrants exercise their right to purchase common stock at a predetermined strike price. It reflects a form of equity financing that provides capital to the firm while increasing the total number of outstanding shares. Investors monitor this to assess the potential for non-dilutive or dilutive capital infusion and the confidence of warrant holders in the company's future equity value.